Inhibrx Biosciences posts a Q1 GAAP loss of $2.15 per share as cash reserves rise to $161.7 million.
Inhibrx Biosciences reported a first-quarter GAAP loss of $2.15 per share, reflecting ongoing operational costs. The company’s cash and cash equivalents stood at $161.7 million as of March 31, 2026, up from $124.2 million at the end of 2025.
The increase in cash reserves suggests improved liquidity, though the company continues to operate at a loss. Comparable losses were not provided for the prior-year period, limiting year-over-year comparisons.
No immediate market reaction was disclosed in the release.